SynthesisBMC infectious diseases2025
Extended-spectrum beta-lactam-resistant Klebsiella pneumoniae in sub-Saharan Africa: a systematic review and meta-analysis from a One Health perspective.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Rising Burden of ESBL-Producing Escherichia coli and Klebsiella pneumoniae in Burkina Faso: A Five-Year Retrospective Analysis.Current microbiology · 2026Article
- Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Klebsiella pneumoniae in humans, animals and the environment in Northwest Amhara, Ethiopia.Scientific reports · 2026Article
- Whole-genome sequencing of MDR K. pneumoniae circulating in Moroccan river ecosystems: a comprehensive genomic analysis of environmental isolates.BMC genomics · 2026Article
- Detection of New Delhi metallo-β-lactamase (blaScientific reports · 2026Article
- Prevalence of extended spectrum beta lactamase and molecular detection of blaInternational microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Resistance gene profiling of beta-lactamase and carbapenemase in gram-negative blood isolates: A tertiary care hospital.PloS one · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae is a critical priority pathogen for which there is a need for new antimicrobials and poses a great public health threat to many parts of the world including sub-Saharan Africa (SSA). This study aims to determine the prevalence of ESBL-producing K. pneumoniae in SSA using a one health perspective, and the predominant ESBL genes in the region.
methodsDatabases such as PubMed, Scopus, Web of Science, Africa Journal Online, and Google Scholar were searched for eligible articles based on pre-set eligibility criteria. After screening of titles, abstracts, and full texts, a meta-analysis using a random-effect model was conducted on the eligible studies to determine the overall and subgroup prevalence of ESBL-producing K. pneumoniae in SSA.
resultsThis meta-analysis included 119 eligible studies from 25 SSA countries in all SSA subregions. The overall prevalence of ESBL-producing K. pneumoniae in SSA is estimated to be 8.6% [95% CI: 6.4-11]. South Africa (18.5%) and Central Africa (4.6%) subregions have the highest and lowest prevalence of ESBL-producing K. pneumoniae in the region, respectively. Additionally, South Africa (23.3%), Kenya (23%), and Nigeria (11.1%) are the top three countries with ESBL-K. pneumoniae. Animal samples were also seen to have the highest prevalence compared to clinical and environmental samples in this study. Lastly, bla
conclusionThe widespread presence of resistant strains in certain regions poses a significant risk of inter-country transmission, highlighting the need for collaborative regional surveillance and control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.